ДИБАС Мохаммед И. (US),ДОНЕЛЛО Джон Е. (US),ДЖИЛ Дэниел В. (US),БЕРК Джеймс Эй. (US)
申请号：
RU2014106328/15
公开号：
RU2014106328A
申请日:
2012.07.22
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A pharmaceutical composition for treating retinal diseases in a patient suffering from such, comprising a therapeutically effective amount of 4-bromo-N-imidazolidin-3-ylidene) -1H-benzimidazole-5-amine or a pharmaceutically acceptable salt thereof, together with pharmaceutically acceptable carriers. 2. A method for treating retinal diseases in a patient suffering from such, comprising administering to said patient a pharmaceutical composition according to Claim 1.3. The method of claim 2, wherein the pharmaceutical composition is administered to the eye. The method of claim 2, wherein the retinal disease is selected from: age-related macular degeneration, wet macular degeneration, dry macular degeneration, geographical atrophy, diabetic retinopathy, diabetic macular edema, retinitis pigmentosa, retinal vein occlusion, neuritis secondary to multiple sclerosis, Stargardt's disease, acute macular neuroretinopathy, optic neuritis and diabetic retinopathy. 5. An industrial product comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent is effective for treating a patient suffering from retinal diseases and where the packaging material contains a label that indicates that said pharmaceutical agent can be used to treat diseases retinas and wherein said pharmaceutical is 4-bromo-N- (imidazolidin-2-ylidene) -1H-benzimidazole-5-amine or fa devel- takovogo.6 acceptable salt thereof. Pharmaceutical composition for neuroprotection of the retina in a patient1. Фармацевтическая композиция для лечения заболеваний сетчатки у пациента, страдающего от таковых, включающая терапевтически эффективное количество 4-бром-N-имидазолидин-3-илиден)-1Н-бензимидазол-5-амина или фармацевтически приемлемой соли такового вместе с фармацевтически приемлемыми носителями.2. Способ для лечения заболеваний сетчатки у пациента, страдающего от таковых, включающий введение указанному пациенту фармацевтической композиции по п.1.
